Geldanamycin and its anti-cancer activities

Cancer Letters

Volumn 290, Issue 1, 2010, Pages 24-35

  Fukuyo, Yayoi ^a   Hunt, Clayton R ^a   Horikoshi, Nobuo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

17 AAG DMAG; BRAF(V600E); Client protein; Geldanamycin; HSP90; MAPK signaling pathway; Reactive oxygen species (ROS)

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BORTEZOMIB; CF 237; CF 483; CHAPERONE; CLOROBIOCIN; CNF 2024; COUMARIN DERIVATIVE; CYCLOPROPARADICICOL; DOCETAXEL; GELDANAMYCIN; GEMCITABINE; GLUTAMIC ACID; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IPI 493; KF 55823; KF 58333; KW 2478; MUTANT PROTEIN; NOVOBIOCIN; RADICICOL; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER CONTROL; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; OVARY CANCER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 77249121048     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.07.010     Document Type: Review

References (105)

1. DeBoer C., Meulman P.A., Wnuk R.J., and Peterson D.H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo) 23 (1970) 442-447
2. Whitesell L., Shifrin S.D., Schwab G., and Neckers L.M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 52 (1992) 1721-1728
3. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., and Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91 (1994) 8324-8328
4. Mimnaugh E.G., Chavany C., and Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271 (1996) 22796-22801
5. Supko J.G., Hickman R.L., Grever M.R., and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36 (1995) 305-315
6. Le Brazidec J.Y., Kamal A., Busch D., Thao L., Zhang L., Timony G., Grecko R., Trent K., Lough R., Salazar T., Khan S., Burrows F., and Boehm M.F. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J. Med. Chem. 47 (2004) 3865-3873
7. Blagg B.S., and Kerr T.D. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med. Res. Rev. 26 (2006) 310-338
8. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005) 761-772
9. Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem. Sci. 24 (1999) 136-141
10. Prodromou C., Roe S.M., Piper P.W., and Pearl L.H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat. Struct. Biol. 4 (1997) 477-482
11. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 (1997) 65-75
12. Sharp S., and Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95 (2006) 323-348
13. Cunningham C.N., Krukenberg K.A., and Agard D.A. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol. Chem. 283 (2008) 21170-21178
14. Roe S.M., Ali M.M., Meyer P., Vaughan C.K., Panaretou B., Piper P.W., Prodromou C., and Pearl L.H. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116 (2004) 87-98
15. Pearl L.H. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15 (2005) 55-61
16. Scholz G.M., Cartledge K., and Hall N.E. Identification and characterization of Harc, a novel Hsp90-associating relative of Cdc37. J. Biol. Chem. 276 (2001) 30971-30979
17. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., Prodromou C., and Pearl L.H. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440 (2006) 1013-1017
18. Ratajczak T., and Carrello A. Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J. Biol. Chem. 271 (1996) 2961-2965
19. Chen S., Sullivan W.P., Toft D.O., and Smith D.F. Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperon. 3 (1998) 118-129
20. Meyer P., Prodromou C., Liao C., Hu B., Roe S.M., Vaughan C.K., Vlasic I., Panaretou B., Piper P.W., and Pearl L.H. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23 (2004) 1402-1410
21. Panaretou B., Siligardi G., Meyer P., Maloney A., Sullivan J.K., Singh S., Millson S.H., Clarke P.A., Naaby-Hansen S., Stein R., Cramer R., Mollapour M., Workman P., Piper P.W., Pearl L.H., and Prodromou C. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell. 10 (2002) 1307-1318
22. Wang X., Venable J., LaPointe P., Hutt D.M., Koulov A.V., Coppinger J., Gurkan C., Kellner W., Matteson J., Plutner H., Riordan J.R., Kelly J.W., Yates III J.R., and Balch W.E. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127 (2006) 803-815
23. Marcu M.G., Chadli A., Bouhouche I., Catelli M., and Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275 (2000) 37181-37186
24. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., and Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 (1997) 239-250
25. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 (1999) 260-266
26. Ali J.A., Orphanides G., and Maxwell A. Nucleotide binding to the 43-kilodalton N-terminal fragment of the DNA gyrase B protein. Biochemistry 34 (1995) 9801-9808
27. Jackson A.P., Maxwell A., and Wigley D.B. Preliminary crystallographic analysis of the ATP-hydrolysing domain of the Escherichia coli DNA gyrase B protein. J. Mol. Biol. 217 (1991) 15-17
28. Marcu M.G., Schulte T.W., and Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92 (2000) 242-248
29. Yun B.G., Huang W., Leach N., Hartson S.D., and Matts R.L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 43 (2004) 8217-8229
30. Chakraborty A., Koldobskiy M.A., Sixt K.M., Juluri K.R., Mustafa A.K., Snowman A.M., van Rossum D.B., Patterson R.L., and Snyder S.H. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl. Acad. Sci. USA 105 (2008) 1134-1139
31. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
32. Xu W., Marcu M., Yuan X., Mimnaugh E., Patterson C., and Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA 99 (2002) 12847-12852
33. Halilovic E., and Solit D.B. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr. Opin. Pharmacol. 8 (2008) 419-426
34. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
35. Garnett M.J., and Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 (2004) 313-319
36. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
37. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., and Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66 (2006) 9483-9491
38. Smalley K.S., Xiao M., Villanueva J., Nguyen T.K., Flaherty K.T., Letrero R., Van Belle P., Elder D.E., Wang Y., Nathanson K.L., and Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 28 (2009) 85-94
39. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
40. Weber C.K., Slupsky J.R., Kalmes H.A., and Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61 (2001) 3595-3598
41. Garnett M.J., Rana S., Paterson H., Barford D., and Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell. 20 (2005) 963-969
42. Grbovic O.M., Basso A.D., Sawai A., Ye Q., Friedlander P., Solit D., and Rosen N. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA 103 (2006) 57-62
43. Ikenoue T., Hikiba Y., Kanai F., Aragaki J., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., Kawakami T., Matsumura M., Kawabe T., and Omata M. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res. 64 (2004) 3428-3435
44. Mercer K., Giblett S., Green S., Lloyd D., DaRocha Dias S., Plumb M., Marais R., and Pritchard C. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65 (2005) 11493-11500
45. Patton E.E., Widlund H.R., Kutok J.L., Kopani K.R., Amatruda J.F., Murphey R.D., Berghmans S., Mayhall E.A., Traver D., Fletcher C.D., Aster J.C., Granter S.R., Look A.T., Lee C., Fisher D.E., and Zon L.I. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15 (2005) 249-254
46. Wellbrock C., Ogilvie L., Hedley D., Karasarides M., Martin J., Niculescu-Duvaz D., Springer C.J., and Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64 (2004) 2338-2342
47. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
48. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., and Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63 (2003) 5198-5202
49. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., and Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 23 (2004) 6292-6298
50. da Rocha Dias S., Friedlos F., Light Y., Springer C., Workman P., and Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65 (2005) 10686-10691
51. Schulte T.W., An W.G., and Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 239 (1997) 655-659
52. Fukuyo Y., Inoue M., Nakajima T., Higashikubo R., Horikoshi N.T., Hunt C., Usheva A., Freeman M.L., and Horikoshi N. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Res. 68 (2008) 6324-6330
53. Mitchell C., Park M.A., Zhang G., Han S.I., Harada H., Franklin R.A., Yacoub A., Li P.L., Hylemon P.B., Grant S., and Dent P. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Mol. Cancer Ther. 6 (2007) 618-632
54. Lewis R.J., Singh O.M., Smith C.V., Skarzynski T., Maxwell A., Wonacott A.J., and Wigley D.B. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 15 (1996) 1412-1420
55. Ohsawa I., Ishikawa M., Takahashi K., Watanabe M., Nishimaki K., Yamagata K., Katsura K., Katayama Y., Asoh S., and Ohta S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 13 (2007) 688-694
56. Chiosis G., and Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol. 1 (2006) 279-284
57. Guo W., Siegel D., and Ross D. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. J. Pharm. Sci. 97 (2008) 5147-5157
58. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., Pak R.H., Ali J.A., Dembski M.S., Hudak J., Patterson J., Penders C., Pink M., Read M.A., Sang J., Woodward C., Zhang Y., Grayzel D.S., Wright J., Barrett J.A., Palombella V.J., Adams J., and Tong J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 103 (2006) 17408-17413
59. Guo W., Reigan P., Siegel D., Zirrolli J., Gustafson D., and Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65 (2005) 10006-10015
60. Gaspar N., Sharp S.Y., Pacey S., Jones C., Walton M., Vassal G., Eccles S., Pearson A., and Workman P. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69 (2009) 1966-1975
61. Ahn S.G., and Thiele D.J. Redox regulation of mammalian heat shock factor 1 is essential for Hsp gene activation and protection from stress. Genes Dev. 17 (2003) 516-528
62. Evans A.R., Limp-Foster M., and Kelley M.R. Going APE over ref-1. Mutat. Res. 461 (2000) 83-108
63. Brummer T., Martin P., Herzog S., Misawa Y., Daly R.J., and Reth M. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 25 (2006) 6262-6276
64. Dey A., and Cederbaum A.I. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway. Arch. Biochem. Biophys. 461 (2007) 275-286
65. Chen W.Y., Chang F.R., Huang Z.Y., Chen J.H., Wu Y.C., and Wu C.C. Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins. J. Biol. Chem. 283 (2008) 17184-17193
66. Burrows F., Zhang H., and Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 3 (2004) 1530-1536
67. Arya R., Mallik M., and Lakhotia S.C. Heat shock genes - integrating cell survival and death. J. Biosci. 32 (2007) 595-610
68. Chen G., Cao P., and Goeddel D.V. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol. Cell. 9 (2002) 401-410
69. Lewis J., Devin A., Miller A., Lin Y., Rodriguez Y., Neckers L., and Liu Z.G. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J. Biol. Chem. 275 (2000) 10519-10526
70. Zhang R., Luo D., Miao R., Bai L., Ge Q., Sessa W.C., and Min W. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24 (2005) 3954-3963
71. Munster P.N., Srethapakdi M., Moasser M.M., and Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 61 (2001) 2945-2952
72. Munster P.N., Basso A., Solit D., Norton L., and Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E.A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7 (2001) 2155-2158. Clin. Cancer Res. 7 (2001) 2228-2236
73. Maloney A., and Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2 (2002) 3-24
74. Stravopodis D.J., Margaritis L.H., and Voutsinas G.E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr. Med. Chem. 14 (2007) 3122-3138
75. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., and Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 (2003) 407-410
76. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., and Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 6 (2004) 507-514
77. Li Y., Zhang T., Schwartz S.J., and Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist. Update 1 (2009)
78. Schnur R.C., Corman M.L., Gallaschun R.J., Cooper B.A., Dee M.F., Doty J.L., Muzzi M.L., Moyer J.D., DiOrio C.I., Barbacci E.G., et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 38 (1995) 3806-3812
79. Chiosis G., Huezo H., Rosen N., Mimnaugh E., Whitesell L., and Neckers L. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol. Cancer Ther. 2 (2003) 123-129
80. Sanderson S., Valenti M., Gowan S., Patterson L., Ahmad Z., Workman P., and Eccles S.A. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 5 (2006) 522-532
81. Hostein I., Robertson D., DiStefano F., Workman P., and Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61 (2001) 4003-4009
82. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., Scher H.I., and Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8 (2002) 986-993
83. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., Simmons L., Maloney A., Raynaud F., Campbell M., Walton M., Lakhani S., Kaye S., Workman P., and Judson I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 4152-4161
84. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., Kelly W.K., DeLaCruz A., Curley T., Heller G., Larson S., Schwartz L., Egorin M.J., Rosen N., and Scher H.I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 13 (2007) 1775-1782
85. Kaur G., Belotti D., Burger A.M., Fisher-Nielson K., Borsotti P., Riccardi E., Thillainathan J., Hollingshead M., Sausville E.A., and Giavazzi R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 10 (2004) 4813-4821
86. Eiseman J.L., Lan J., Lagattuta T.F., Hamburger D.R., Joseph E., Covey J.M., and Egorin M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55 (2005) 21-32
87. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., and Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 56 (2005) 126-137
88. Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., and Sausville E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 56 (2005) 115-125
89. J. Lancet, M. Baer, I. Gojo, M. Burton, M. Quinn, S. Tighe, K. Bhalla, K. Kersey, S. Wells, Z. Zhong, et al., Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of intravenous alvespimycin (KOS-1022) in patients with refractory hematological malignancies, in: ASH Annual Meeting, 2006.
90. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., and Hudis C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 25 (2007) 5410-5417
91. J. Lee, L. Grenier, E. Holson, K. Slocum, J. Coco, J. Ge, E. Normant, J. Hoyt, A. Lim, J. Cushing, J. Sydor, J. Wright, IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class, in: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2008.
92. L. Sequist, L. Janne, J. Sweeney, J. Walker, D. Grayzel, T. Lynch, Phase 1/2 trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status, in: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, 2007.
93. A. Van den Abbeele, J. Yap, D. Grayzel, J. Walker, G. Demetri, Inhibition and flare patterns of metabolic response to the Heat Shock Protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy, in: American Society of Clinical Oncology Annual Meeting, 2007.
94. Zhang H., Yang Y.C., Zhang L., Fan J., Chung D., Choi D., Grecko R., Timony G., Karjian P., Boehm M., and Burrows F. Dimeric ansamycins - a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Int. J. Cancer 120 (2007) 918-926
95. Delmotte P., and Delmotte-Plaque J. A new antifungal substance of fungal origin. Nature 171 (1953) 344
96. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., and Neckers L.M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperon. 3 (1998) 100-108
97. Yamamoto K., Garbaccio R.M., Stachel S.J., Solit D.B., Chiosis G., Rosen N., and Danishefsky S.J. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew. Chem. Int. Ed. Engl. 42 (2003) 1280-1284
98. Agatsuma T., Ogawa H., Akasaka K., Asai A., Yamashita Y., Mizukami T., Akinaga S., and Saitoh Y. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg. Med. Chem. 10 (2002) 3445-3454
99. Soga S., Shiotsu Y., Akinaga S., and Sharma S.V. Development of radicicol analogues. Curr. Cancer Drug Targets 3 (2003) 359-369
100. Holdgate G.A., Tunnicliffe A., Ward W.H., Weston S.A., Rosenbrock G., Barth P.T., Taylor I.W., Pauptit R.A., and Timms D. The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. Biochemistry 36 (1997) 9663-9673
101. Burlison J.A., Avila C., Vielhauer G., Lubbers D.J., Holzbeierlein J., and Blagg B.S. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J. Org. Chem. 73 (2008) 2130-2137
102. Camphausen K., and Tofilon P.J. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin. Cancer Res. 13 (2007) 4326-4330
103. Kobayashi S., Nantz R., Kitamura T., Higashikubo R., and Horikoshi N. Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. Oncogene 24 (2005) 3011-3019
104. Solit D.B., Basso A.D., Olshen A.B., Scher H.I., and Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63 (2003) 2139-2144
105. McCollum A.K., Lukasiewicz K.B., Teneyck C.J., Lingle W.L., Toft D.O., and Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol. Cancer Ther. 7 (2008) 3256-3264